Overview

* Intellia Q3 net loss narrows to $101.3 mln, collaboration revenue rises

* FDA places clinical hold on MAGNITUDE trials due to safety concerns

* Enrollment completed in Phase 3 HAELO trial, topline data expected mid-2026

Outlook

* Company suspends milestone guidance for nex-z pending regulatory alignment

* Intellia expects lonvo-z topline data by mid-2026

* Company anticipates U.S. commercial launch of lonvo-z in 1H27

Result Drivers

* PHASE 3 ENROLLMENT COMPLETED - Enrollment completed in Phase 3 HAELO trial of lonvo-z, topline data expected mid-2026

* COLLABORATION REVENUE INCREASE - Collaboration revenue rose due to cost reimbursements from Regeneron Pharmaceuticals

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $13.78

Collabor mln

ation

Revenue

Q3 Net -$101.32

Income mln

Q3 Basic -$0.92

EPS

Q3 $125.26

Operatin mln

g

Expenses

Q3 -$111.48

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 9 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Intellia Therapeutics Inc ( NTLA ) is $24.50, about 44.6% above its November 5 closing price of $13.57

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)